This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the worldwide release of the high performance ISOLATE II range of nucleic acid purification kits.
Based on filter membrane spin column technology with simple bind-wash-elute steps; the new Bioline ISOLATE II kits are designed for fast and efficient isolation of DNA or RNA from a wide range of biological materials. By using ISOLATE II kits, researchers can expect higher yields, higher purity and greater reproducibility when compared to previous generation nucleic acid purification kits.
Marco Calzavara, President of Bioline commented, “With ISOLATE II nucleic acid purification kits, researchers can now quickly achieve the purity and yield necessary for high-performance PCR and real time PCR experiments. This makes ISOLATE II the perfect complement to our widely used PCR reagents.”
Richard L. Eberly, President of Meridian Life Science, Inc., stated, “We are delighted to release the next generation of nucleic acid purification kits, ISOLATE II, to build on the rapidly expanding portfolio of highly specialized molecular biology reagents from Bioline. We are committed to our life science customers and to bringing innovation and quality products; such as the line of ISOLATE II kits to the research laboratory, clinical diagnostic laboratories, and biotechnology companies.”
Ten new DNA and RNA ISOLATE II kits are available now and feature both DNA and RNA extraction kits for a wide range of starting samples and tissues types.
For complete information, please visit
ABOUT MERIDIAN BIOSCIENCE, INC.
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and biotech companies in more than 60 countries around the world. The Company’s shares are traded on NASDAQ’s Global Select Market, symbol VIVO. Meridian's website address is